Skip to main content

Investigación y educación

Submitted by remote_content on

Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia. Pharmacoecon Open.

Investigación y Educación

Gil F. 6/11/2022

Objective
The aim of this study was to evaluate the cost effectiveness of tofacitinib versus other treatment options currently available in Colombia in naïve to biologics (first-line) and exposed to biologics (second-line) patients with moderate to severe active ulcerative colitis (UC).

Conclusion
The analysis suggests that in Colombia, treatment with tofacitinib for patients with moderate-to-severe UC is a cost-effective option in both lines compared with other treatment options.

Read full article

Artículos que te pueden interesar

Medicina Interna

Characteristics and Outcomes of Heart Failure Patients from a Middle- Income Country: The RECOLFACA Registry. Glob Heart.

August 18, 2022

Leer más

Medicina Interna

"Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context. Blood Adv. "

August 10, 2021

Leer más

Medicina Interna

Herramientas para identificar consumo y desperdicio de la dieta hospitalaria. Revisión Sistemática. Rev. chil. nutr.vol.49 no.2 Santiago

April 1, 2022

Leer más